Agilent Technologies stock (US00846U1016): RBC keeps bullish stance before Q2 earnings

RBC Capital Markets reaffirmed an Outperform rating on Agilent Technologies on May 27, 2026, just as the company prepared to report fiscal second-quarter results after the close.

Agilent Technologies drew fresh attention on May 27, 2026, after RBC Capital Markets reiterated an Outperform rating and set a $153 price target, while the company headed into fiscal second-quarter earnings after the close. The stock sits in the U.S. life-sciences tools and laboratory equipment space, a sector watched closely by retail investors for demand trends in diagnostics, pharma, and research spending.GuruFocus as of 05/27/2026

Agilent Technologies is expected to report fiscal Q2 2026 EPS of about $1.40 on revenue near $1.80 billion, according to market coverage published on May 27, 2026. For U.S. investors, that makes the print a near-term catalyst not only for the company’s own shares but also for sentiment across the broader tools and diagnostics segment.Barchart as of 05/27/2026

As of: 27.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Agilent Technologies Inc.
• Sector/industry: Life sciences tools and laboratory instruments
• Headquarters/country: United States
• Core markets: Life sciences, diagnostics, applied chemical markets
• Key revenue drivers: Instruments, consumables, software, services
• Home exchange/listing venue: NYSE: A
• Trading currency: USD

Agilent Technologies: core business model

Agilent designs and sells measurement instruments, consumables, software, and services used in laboratories and industrial testing. Its customer base spans life sciences, diagnostics, and applied chemical markets, which ties the business to R&D budgets, regulated testing demand, and broad trends in healthcare and industrial quality control.MarketScreener as of 05/27/2026

That mix matters for U.S. investors because Agilent is not a pure healthcare or software stock; it sits in a hybrid category where recurring consumables and service revenue can cushion cyclicality in instrument sales. The market often treats that combination as a quality factor, especially when spending visibility in labs and pharma improves.

Main revenue and product drivers for Agilent Technologies

Available market coverage points to three broad product families: electronic measurement instruments, bio-analytical measurement instruments, and semiconductor-related measurement tools. In practical terms, that means results are influenced by both scientific lab activity and parts of the industrial technology cycle.MarketScreener as of 05/27/2026

RBC’s May 27 note argued that Agilent can deliver stronger organic growth than peers, citing an expected 5.5% growth rate versus 4.5% for competitors from 2026 to 2028. The same report also highlighted a valuation framework that used an approximately 18-times forward EBITDA multiple, which suggests the shares are being judged on both growth and premium quality metrics.GuruFocus as of 05/27/2026

More broadly, the setup ahead of earnings is straightforward: if management confirms resilient end demand and preserves guidance credibility, the stock can trade on fundamentals rather than valuation anxiety. If results or commentary disappoint, the premium multiple cited by analysts could become a focal point for sellers.

Conclusion

Agilent enters its fiscal Q2 report with a clear short-term catalyst and a fresh bullish rating from RBC Capital Markets. The company’s appeal rests on recurring demand in laboratory and diagnostics markets, but its shares also carry valuation expectations that can amplify reaction to earnings and guidance. For U.S. investors, the next print will matter because it can test whether the market still rewards the stock’s growth profile with a premium multiple.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.